Evidence map›Paper›PMID 29402273›Full record

ArticleLipids in health and disease2018

In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model.

Antonietta Stellavato, Anna Virginia Adriana Pirozzi, Francesca de Novellis, Ilaria Scognamiglio, Valentina Vassallo, Andrea Maria Giori, Mario De Rosa, Chiara Schiraldi

Erratum issuedAbstract read
In one paragraph

Article in Lipids in health and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Antonietta StellavatoDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Anna Virginia Adriana PirozziDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Francesca de NovellisDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Ilaria ScognamiglioDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Valentina VassalloDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Andrea Maria GioriR&D - IBSA Farmaceutici Italia, Lodi, Italy.
Mario De RosaDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Chiara SchiraldiDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, Università della Campania "Luigi Vanvitelli", Naples, Italy. chiara.schiraldi@unicampania.it.ORCID http://orcid.org/0000-0002-1066-843X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSteatosis is a chronic liver disease that depends on the accumulation of intracellular fatty acids. Currently, no drug treatment has been licensed for steatosis; thus, only nutritional guidelines are indicated to reduce its progression. The aim of this study is to combine different nutraceutical compounds in order to evaluate their synergistic effects on a steatosis in vitro model compared to their separate use. In particular, three different formulations based on silymarin, curcumin, vitamin E, docosahexaenoic acid (DHA), choline, and phosphatidylcholine were assayed.

methodsHuman hepatocellular carcinoma cells (HepG2 cell line) were treated with a mixture of fatty acids in order to induce an in vitro model of steatosic cells, and then the amount of intracellular fat was evaluated by Oil Red O staining. The peroxisome proliferator-activated receptors α and γ (PPARα and γ) expression, closely correlated to lipid metabolism, was evaluated. The efficiency of these receptors was evaluated through the study of LPL mRNA expression, a marker involved in the lipolysis mechanism. Superoxide dismutase (SOD-2) and malondialdehydes (MDA) in lipid peroxidation were assayed as specific biomarkers of oxidative stress. In addition, experiments were performed using human liver cells stressed to obtain a steatosis model. In particular, the content of the intracellular fat was assayed using Oil Red O staining, the activation of PPARα and γ was evaluated through western blotting analyses, and the LPL mRNA expression level was analyzed through qRT-PCR.

resultsAll formulations proved effective on lipid content reduction of about 35%. The oxidative stress damage was reduced by all the substances separately and even more efficiently by the same in formulation (i.e. Formulation 1 and Formulation 3, which reduced the SOD-2 expression and induced the PPARs activation). Lipid peroxidation, was reduced about 2 fold by foormulation2 and up to 5 fold by the others compared to the cells pretreated with H

conclusionsOur results proved that the formulations tested could be considered suitable support to face steatosis disease beside the mandatory dietetic regimen.

Indexed as

Dietary SupplementsDrug SynergismCholineCurcuminDocosahexaenoic AcidsDrug CombinationsDrug CompoundingFatty LiverHep G2 CellsHumansLipid PeroxidationLiverPhosphatidylcholinesPPAR alphaPPAR gammaSilymarinCholineCurcuminDocosahexaenoic AcidsDrug CombinationsPhosphatidylcholinesPPAR alphaPPAR gammaSilymarinVitamin EHepG2Normal liver cellsNutraceutical compoundsOxidative stressPPARs expressionSteatosis in vitro model

Identifiers

PMID29402273
PMCPMC5800044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.